Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Avanos Medical, Inc. | avns-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: November 6, 2018
(Date of earliest event reported)
Avanos Medical, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-36440 |
46-4987888 |
|
(State or other jurisdiction of incorporation) |
(Commission file number) |
(I.R.S. Employer Identification No.) |
|
|
|
|
|
5405 Windward Parkway Suite 100 South Alpharetta, Georgia |
|
30004 |
|
(Address of principal executive offices) |
|
(Zip code) |
Registrant’s telephone number, including area code: (678) 425-9273
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
The Company announced its results of operations for the three and nine months ended September 30, 2018 in a press release dated November 6, 2018 , that is attached and incorporated herein by reference as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
|
(d) |
Exhibits. |
The following exhibits are filed with this Current Report on Form 8-K.
|
Exhibit Number |
|
Description |
|
|
Press release issued by Avanos Medical, Inc. on November 6, 2018. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
AVANOS MEDICAL, INC. |
|
|
|
|
|
|
|
|
Date: |
November 6, 2018 |
|
By: |
/s/ S. Ross Mansbach |
|
|
|
|
|
S. Ross Mansbach Vice President, Deputy General Counsel and Corporate Secretary |